Tecovirimat for monkeypox

Affiliations

¹ Department of Medicine (Halani, Wu), and Division of Clinical Pharmacology and Toxicology (Wu), University of Toronto; Department of Pharmacy (Leong), University Health Network, Toronto, Ont. Sheliza.halani@mail.utoronto.ca.
² Department of Medicine (Halani, Wu), and Division of Clinical Pharmacology and Toxicology (Wu), University of Toronto; Department of Pharmacy (Leong), University Health Network, Toronto, Ont.

Sheliza Halani et al. CMAJ. 2022.

. 2022 Nov 28;194(46):E1573.

doi: 10.1503/cmaj.221210.

¹ Department of Medicine (Halani, Wu), and Division of Clinical Pharmacology and Toxicology (Wu), University of Toronto; Department of Pharmacy (Leong), University Health Network, Toronto, Ont. Sheliza.halani@mail.utoronto.ca.
² Department of Medicine (Halani, Wu), and Division of Clinical Pharmacology and Toxicology (Wu), University of Toronto; Department of Pharmacy (Leong), University Health Network, Toronto, Ont.

No abstract available

Conflict of interest statement

Competing interests: None declared.

1. Russo AT, Grosenbach DW, Chinsangaram J, et al. . An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev Anti Infect Ther 2021;19:331–44. - PMC - PubMed
1. Monkeypox antiviral guidance for health care providers. Toronto: Ontario Ministry of Health; 2022. Available: https://www.toronto.ca/wp-content/uploads/2022/07/8ed0-Monkeypox-Antivir... (accessed 2022 Aug. 15).
1. Grosenbach DW, Honeychurch K, Rose EA, et al. . Oral tecovirimat for the treatment of smallpox. N Engl J Med 2018; 379:44–53. - PMC - PubMed
1. Thornhill JP, Barkati S, Walmsley S, et al. SHARE-net Clinical Group. Monkeypox virus infection in humans across 16 countries: April–June 2022. N Engl J Med 2022;387:679–91. - PubMed
1. Product monograph including patient medication information: PrTPOXX®. Corvallis (OR): SIGA Technologies, Inc.; 2021. Available: https://pdf.hres.ca/dpd_pm/00063782.PDF (accessed 2022 Aug. 15).